Chimerix Inc. (CMRX)

2.38
NASDAQ : Health Technology
Prev Close 2.36
Day Low/High 2.32 / 2.40
52 Wk Low/High 1.74 / 4.40
Avg Volume 369.90K
Exchange NASDAQ
Shares Outstanding 61.27M
Market Cap 144.60M
EPS -1.40
P/E Ratio N/A
Div & Yield N.A. (N.A)
Short Interest In Chimerix Expands By 15.4%

Short Interest In Chimerix Expands By 15.4%

The most recent short interest data has been released by the NASDAQ for the 07/15/2015 settlement date, which shows a 405,514 share increase in total short interest for Chimerix Inc. , to 3,040,944, an increase of 15.39% since 06/30/2015.

Trade-Ideas: Chimerix (CMRX) Is Today's New Lifetime High Stock

Trade-Ideas: Chimerix (CMRX) Is Today's New Lifetime High Stock

Trade-Ideas LLC identified Chimerix (CMRX) as a new lifetime high candidate

Interesting CMRX Put And Call Options For February 2016

Interesting CMRX Put And Call Options For February 2016

Investors in Chimerix Inc. saw new options begin trading this week, for the February 2016 expiration.

Chimerix (CMRX) Reaches New Lifetime High Today

Chimerix (CMRX) Reaches New Lifetime High Today

Trade-Ideas LLC identified Chimerix (CMRX) as a new lifetime high candidate

Chimerix (CMRX) Is Today's Pre-Market Mover With Heavy Volume Stock

Chimerix (CMRX) Is Today's Pre-Market Mover With Heavy Volume Stock

Trade-Ideas LLC identified Chimerix (CMRX) as a pre-market mover with heavy volume candidate

Chimerix Announces First Quarter Financial Results

Chimerix Announces First Quarter Financial Results

Company Plans to Initiate Brincidofovir SURPASS and SUSTAIN Studies in Kidney Transplant Recipients in Second Half 2015

Commit To Purchase Chimerix At $25, Earn 10.1% Annualized Using Options

Commit To Purchase Chimerix At $25, Earn 10.1% Annualized Using Options

Investors considering a purchase of Chimerix Inc. shares, but tentative about paying the going market price of $35.40/share, might benefit from considering selling puts among the alternative strategies at their disposal.

CMRX: Insiders vs. Shorts

CMRX: Insiders vs. Shorts

The most recent short interest data was recently released by the NASDAQ for the 02/27/2015 settlement date, and Chimerix Inc. is one of the most shorted stocks of the Russell 3000, based on 8.46 "days to cover" versus the median component at 5.59.

Chimerix (CMRX) Stock Declined Today Following Wider Than Expected Quarterly Loss

Chimerix (CMRX) Stock Declined Today Following Wider Than Expected Quarterly Loss

Chimerix (CMRX) shares fell after the company missed analysts' fourth quarter net loss expectations.

Chimerix Announces Fourth Quarter And Full Year 2014 Financial Results

Chimerix Announces Fourth Quarter And Full Year 2014 Financial Results

Company to Hold Conference Call at 8:30am ET Today

Chimerix Presents Update On Preliminary Data From AdVise Study Of Brincidofovir For Adenovirus Infection At BMT Tandem Meetings

Chimerix Presents Update On Preliminary Data From AdVise Study Of Brincidofovir For Adenovirus Infection At BMT Tandem Meetings

Data Further Support Potential for Improved Survival of Life-Threatening Infection

Chimerix Focusing Efforts On CMV And Adenovirus Pivotal Trials

Chimerix Focusing Efforts On CMV And Adenovirus Pivotal Trials

Brincidofovir Will Not Be Considered in Further Clinical Trials in Ebola Virus Disease

First Week of CMRX March 20th Options Trading

First Week of CMRX March 20th Options Trading

Investors in Chimerix Inc. saw new options begin trading this week, for the March 20th expiration.

Cramer: A Toast to Beer Companies Benefiting From Lower Oil Prices

Cramer: A Toast to Beer Companies Benefiting From Lower Oil Prices

Constellation Brands is among the companies getting a sales boost from the drop in oil prices, Cramer says. But is it time to finally buy energy stocks?

Chimerix Provides Update On Brincidofovir Pivotal Phase 3 AdVise Trial For The Treatment Of Adenovirus

Chimerix Provides Update On Brincidofovir Pivotal Phase 3 AdVise Trial For The Treatment Of Adenovirus

-Additional Updates on Brincidofovir for Ebola Virus Disease and Kidney Transplant Recipients-

TheStreet Quant Rating: D (Sell)